Chikungunya virus (CHIKV) infection causes acute disease characterized by fever, rash and arthralgia, which progresses to severe and chronic arthritis in up to 50% of patients. Moreover, CHIKV infection can be fatal in infants or immunocompromised individuals and has no approved therapy or prevention. This phase 1, first-in-human, randomized, placebo-controlled, proof-of-concept trial conducted from January 2019 to June 2020 evaluated the safety and pharmacology of mRNA-1944, a lipid nanoparticle-encapsulated messenger RNA encoding the heavy and light chains of a CHIKV-specific monoclonal neutralizing antibody, CHKV-24 ( NCT03829384 ). The primary outcome was to evaluate the safety and tolerability of escalating doses of mRNA-1944 administered via intravenous infusion in healthy participants aged 18–50 years. The secondary objectives included determination of the pharmacokinetics of mRNA encoding for CHKV-24 immunoglobulin heavy and light chains and ionizable amino lipid component and the pharmacodynamics of mRNA-1944 as assessed by serum concentrations of mRNA encoding for CHKV-24 immunoglobulin G (IgG), plasma concentrations of ionizable amino lipid and serum concentrations of CHKV-24 IgG. Here we report the results of a prespecified interim analysis of 38 healthy participants who received intravenous single doses of mRNA-1944 or placebo at 0.1, 0.3 and 0.6 mg kg −1 , or two weekly doses at 0.3 mg kg −1 . At 12, 24 and 48 h after single infusions, dose-dependent levels of CHKV-24 IgG with neutralizing activity were observed at titers predicted to be therapeutically relevant concentrations (≥1 µg ml −1 ) across doses that persisted for ≥16 weeks at 0.3 and 0.6 mg kg −1 (mean t 1/2 approximately 69 d). A second 0.3 mg kg −1 dose 1 week after the first increased CHKV-24 IgG levels 1.8-fold. Adverse effects were mild to moderate in severity, did not worsen with a second mRNA-1944 dose and none were serious. To our knowledge, mRNA-1944 is the first mRNA-encoded monoclonal antibody showing in vivo expression and detectable ex vivo neutralizing activity in a clinical trial and may offer a treatment option for CHIKV infection. Further evaluation of the potential therapeutic use of mRNA-1944 in clinical trials for the treatment of CHIKV infection is warranted. An mRNA-based therapeutic can drive expression of a functional antibody in humans at levels capable of neutralizing Chikungunya virus ex vivo.
【저자키워드】 viral infection, Infectious diseases, Preventive medicine, 【초록키워드】 Treatment, neutralizing antibody, IgG, Arthritis, clinical trial, therapy, Trial, antibody, knowledge, severity, monoclonal antibody, Human, Infection, Infant, Randomized, serum, Neutralizing activity, Immunoglobulin, mRNA, Fever, therapeutic, Mild, Placebo, Neutralizing, in vivo, disease, expression, moderate, patients, Rash, placebo-controlled, single dose, monoclonal, Concentration, dose, intravenous, Ex vivo, plasma concentration, Messenger RNA, Tolerability, Adverse, Primary outcome, participant, interim analysis, therapeutic use, arthralgia, offer, Administered, Effect, Chikungunya virus, predicted, evaluate, healthy, detectable, evaluated, approved, conducted, characterized, functional, cause, dose-dependent, IgG level, immunocompromised individual, mRNA-based, 【제목키워드】 monoclonal antibody, Neutralizing activity, mRNA, phase 1 trial, Chikungunya virus,